Propandrol 100mg/ml 10x1ml Ampullen by Balkan Pharmaceuticals

Usage

1. Review the compound's historical clinical dosing guidelines (25–100 mg EOD range) and select a starting dose appropriate to your experience level and goal, as established in androgen pharmacology literature.
2. Confirm the Propandrol ampoule's lot code and expiry date printed on the carton — Balkan Pharmaceuticals' traceability system links each code to batch HPLC and LAL test records.
3. Snap the ampoule open at the colour-coded neck ring using a clean ampoule file or opener; the glass-fusion seal is designed for single-break sterile access in keeping with GMP Annex 1 closure standards.
4. Draw the full 1 ml (100 mg) or your measured partial volume using a 19–21 gauge drawing needle, then switch to an appropriate gauge injection needle for intramuscular administration into the gluteus, vastus lateralis, or deltoid.
5. Administer via deep intramuscular injection using aseptic technique; rotate injection sites across the every-other-day schedule to respect the tissue-recovery principle first described in clinical injection-site rotation protocols from mid-20th century androgen therapy literature.
6. Discard the used ampoule immediately — the single-dose format means no portion of the opened ampoule should be stored or reused; log each administration date to maintain the consistent spacing that the propionate ester's pharmacokinetics demand.

Warnings

Frequently asked questions

Where did Testosterone Propionate originally come from and who first developed it?

Testosterone Propionate was first synthesised and characterised in Germany in the late 1930s, with Schering AG among the pioneering institutions involved in its development. Scientists attached a short propanoic acid chain to the testosterone molecule to create a compound with a more manageable pharmacokinetic profile than raw testosterone, making it suitable for clinical injection. It became the first esterified testosterone approved for therapeutic use in humans.

When was Testosterone Propionate first introduced into medical practice?

Testosterone Propionate entered clinical use in the late 1930s — approximately 1937–1939 — making it roughly two decades older than Testosterone Enanthate (introduced in the 1950s) and Testosterone Cypionate. Its early adoption by endocrinologists treating hypogonadism and delayed puberty established the pharmacological template that all subsequent testosterone esters have followed. This historical precedence is why propionate is often called the 'original' therapeutic testosterone ester.

How has the clinical and athletic use of Testosterone Propionate evolved since the 1930s?

Initially confined to endocrine medicine for conditions such as hypogonadism and androgen deficiency, Testosterone Propionate's use expanded into sports science from the 1950s onward as researchers documented its effects on nitrogen retention and skeletal muscle protein synthesis. By the 1980s it was widely adopted in competitive athletics for its fast-clearing pharmacokinetic profile. Today it remains relevant in both therapeutic testosterone replacement therapy and performance contexts for users who require a short-acting androgen.

Why does Propandrol come in 10 individual 1ml ampoules rather than a multi-dose vial?

Single-dose 1 ml ampoules eliminate the sterility risks associated with repeated needle puncture into multi-draw vials. Each glass ampoule is sealed by fusion during the filling process — a container-closure method validated under EU GMP Annex 1 — meaning every injection draws from a never-opened, sterile unit. This format also enables precise dose tracking because each ampoule represents exactly 100 mg of Testosterone Propionate with no residual volume ambiguity.

Is 100mg/ml a standard concentration for Testosterone Propionate, and why does Propandrol use it?

Yes, 100 mg/ml is the classical and most historically consistent concentration for Testosterone Propionate injectables, directly reflecting the dose density used in original 1930s–1950s clinical protocols. Higher concentrations exist in the market, but 100 mg/ml allows precise measurement of smaller dose increments — important given the every-other-day injection schedule typically associated with propionate — and produces less injection-site discomfort than more concentrated formulations. Balkan Pharmaceuticals' choice aligns Propandrol with the compound's established clinical heritage. (2) angle_used

Manufacturer

Balkan Pharmaceuticals approaches formulation development as an iterative, evidence-anchored process: when the company's technical team selected Testosterone Propionate as the active ingredient for Propandrol, the formulation parameters — 100 mg/ml concentration, refined carrier oil composition, and fill volume of exactly 1 ml — were chosen to replicate the dose density of the compound's original clinical presentations from the 1930s while meeting the tighter analytical tolerances demanded by current EU GMP Annex 1 standards. Innovation at Balkan is not limited to introducing novel molecules; it also encompasses re-engineering historically validated compounds with modern quality infrastructure. The Chișinău manufacturing site applies validated in-process controls at every stage of Propandrol's production: raw Testosterone Propionate active pharmaceutical ingredient is tested against identity and purity specifications on intake, the compounded solution undergoes HPLC quantification to confirm 100 mg/ml within the accepted analytical range, and the final filled ampoules are subjected to LAL (Limulus Amebocyte Lysate) endotoxin testing before batch release. This layered quality framework — combining a century-validated molecule with 21st-century analytical methods — represents Balkan Pharmaceuticals' central formulation development philosophy: demonstrated clinical heritage plus rigorous modern verification.